Tag Archives: extended-release niacin
March 2009 Br J Cardiol 2009;16:90–7
Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia
Gilbert Gleim, Christie M Ballantyne, Nancy Liu, Sally Thompson-Bell, Christine McCrary Sisk, Richard C Pasternak, Yale Mitchel, John F Paolini
Introduction Large intervention studies suggest that while lowering low-density lipoprotein cholesterol (LDL-C) is beneficial, it is insufficient to prevent the majority of coronary heart disease (CHD) events. Niacin improves the overall lipid profile, LDL-C and triglycerides (TG) and is the most effective agent for raising high-density lipoprotein cholesterol (HDL-C) levels.1 Co-administration of niacin with a statin offers the potential for additional lipid management, but the use of niacin has been limited due to associated flushing, mediated primarily by prostaglandin D2 (PGD2).2 Flushing of the face and trunk occurs in nearly all patient
For healthcare professionals only
